Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
13.84
+0.77 (5.89%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Adlai Nortye Earnings Call Transcripts
Fiscal Year 2026
-
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.